Insiders tell CNN the FDA’s AI is “hallucinating” studies and can’t access key documents. Agency leaders insist the AI is ...

FDA staffers aren't making progress with new agency chatbot, billed as a game-changer for lengthy approval processes. - Thomas Fuller / SOPA Images /LightRocket via Getty Images Yahoo is using AI to ...

A new FDA program will use a two-phase approach to help boost domestic drug manufacturing, while OpenAI is leaning into health care with the launch of GPT-5.

As agentic AI advances, it will impact patient-facing healthcare delivery models, while new questions around the ...

Revolution Medicines Inc. (NASDAQ: RVMD) is one of the best upside stocks to invest in now. Earlier on July 23, Revolution ...

On June 2, 2025, FDA announced the launch of Elsa, a generative AI tool designed to “help employees—from scientific reviewers to investigators—work more efficiently.” Per FDA, the tool ...

The FDA’s AI program needs to have guardrails in place to ensure it’s working properly. No matter what AI is used for at the FDA, processes must be in place to ensure fairness and accuracy ...

On June 2, the FDA dropped the other shoe, saying it had launched a generative AI tool called “Elsa” to help scientific reviewers and investigators work more efficiently.

FDA officials want to leverage AI for drug and device approval, animal testing, and data processing, as the Trump administrations slashes its workforce.

Following FDA’s first AI-assisted medical product review, the agency has committed to expanding the use of generative AI across all centers by June 30, 2025. Commissioner Makary emphasized the ...